Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs.
Low molecular weight heparins (LMWHs) are recognised as the preferred anticoagulants in the prevention and treatment of venous thromboembolism. Anti-Factor Xa (anti-FXa) levels are used to monitor the anticoagulant effect of LMWHs and such assays are routinely employed in hospital diagnostic laboratories. In this study, a fluorogenic anti-FXa assay was developed using a commercially available fluorogenic substrate with an attached 6-amino-1-naphthalene-sulfonamide (ANSN) fluorophore and was used for the determination of two LMWHs, enoxaparin and tinzaparin and the heparinoid, danaparoid. The assay was based on the complexation of heparinised plasma with 100 nM exogenous FXa and 25 μM of the fluorogenic substrate Mes-D-LGR-ANSN (C(2)H(5))(2) (SN-7). The assay was tested with pooled plasma samples spiked with anticoagulant concentrations in the range 0-1.6 U mL(-1). The statistically sensitive assay range was 0-0.4 U mL(-1) for enoxaparin and tinzaparin and 0-0.2 U mL(-1) for danaparoid, with assay variation typically below 10.5%. This assay was then compared with a previously published fluorogenic anti-FXa assay developed with the peptide substrate, methylsulfonyl-D: -cyclohexylalanyl-glycyl-arginine-7-amino-4-methylcoumarin acetate (Pefafluor FXa). Both assays were compared in terms of fluorescence intensity, lag times and sensitivity to anticoagulants.
Biomedical Diagnostics Institute, National Centre for Sensor Research, Dublin City University, Dublin 9, Ireland.
Vanessa
V
Castro-López
Leanne F
LF
Harris
James S
JS
O'Donnell
Anthony J
AJ
Killard
D000925:Anticoagulants / Q000032:analysis / Q000097:blood* / Q000494:pharmacology; D002809:Chondroitin Sulfates / Q000032:analysis / Q000097:blood / Q000494:pharmacology; D003871:Dermatan Sulfate / Q000032:analysis / Q000097:blood / Q000494:pharmacology; D017984:Enoxaparin / Q000032:analysis / Q000097:blood / Q000494:pharmacology; D015951:Factor Xa / Q000378:metabolism; D065427:Factor Xa Inhibitors; D005456:Fluorescent Dyes / Q000737:chemistry; D006495:Heparin, Low-Molecular-Weight / Q000032:analysis / Q000097:blood* / Q000494:pharmacology; D006496:Heparinoids / Q000032:analysis / Q000097:blood / Q000494:pharmacology; D006497:Heparan Sulfate / Q000032:analysis / Q000097:blood / Q000494:pharmacology; D006801:Humans; D012680:Sensitivity and Specificity; D013050:Spectrometry, Fluorescence / Q000379:methods*; D013449:Sulfonamides / Q000737:chemistry; D000078222:Tinzaparin
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D017984:Enoxaparin; D015951:Factor Xa; D065427:Factor Xa Inhibitors; D005456:Fluorescent Dyes; D006495:Heparin, Low-Molecular-Weight; D006496:Heparinoids; D006497:Heparan Sulfate; D013449:Sulfonamides; D000078222:Tinzaparin; C082094:6-amino-1-naphthalenesulfonamide; C035838:danaparoid